NCT05285878View on ClinicalTrials.gov

Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 28, 2022

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Interstitial FibrosisKidney Transplant; ComplicationsKidney Transplant RejectionKidney Transplant Failure and RejectionKidney Transplant FailureKidney Failure, ChronicGraft Rejection
Interventions
DRUG

Fingolimod

0.5 mg daily

DRUG

Placebo

0.5 mg daily

Trial Locations (1)

77030

Houston Methodist Research Institute, Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER